

9-1-2022

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome.

Jessica Yi
Thomas Jefferson University

Marinos Dalakas
Thomas Jefferson University

Follow this and additional works at: <https://jdc.jefferson.edu/neurologyfp>



Part of the [Neurology Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Yi, Jessica and Dalakas, Marinos, "Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome." (2022). *Department of Neurology Faculty Papers*. Paper 298.

<https://jdc.jefferson.edu/neurologyfp/298>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome

Jessica Yi, MD, and Marinos C. Dalakas, MD, FAAN

Neurol Neuroimmunol Neuroinflamm 2022;9:e200011. doi:10.1212/NXL.0000000000200011

Correspondence

Dr. Dalakas
marinos.dalakas@jefferson.edu and
mdalakas@med.uoa.gr

Abstract

Background and Objectives

IVIg has been the preferred immunotherapy in stiff-person syndrome (SPS) based on a 3-month controlled trial, but whether it is also effective in inducing long-term benefits or arresting disease progression is unknown. The information is needed because SPS is a progressively disabling disease and IVIg is liberally used as chronic therapy without efficacy data. The present study explores the long-term effects of IVIg in the largest cohort of well-characterized patients with SPS followed by the same clinicians over 10 years.

Methods

Data of 36 patients (32 glutamic acid decarboxylase [GAD] positive), diagnosed and treated with monthly maintenance IVIg by the same neurologists, were analyzed. Response was assessed by physician-observed changes, patients' reports of symptom improvement, modified Rankin Scale (mRS) scores, and dependency trials evaluating symptom recurrence after stopping IVIg, prolonging infusion frequency, decreasing monthly dose, or wearing-off effects in between doses. Clinically meaningful long-term response was defined by improved mRS scores, improvement in physician-assessed stiffness, balance and gait, and functional decline with dependency trials.

Results

Twenty-four of 36 (67%) patients had clinically meaningful response over a median 40-month period. Patients with improved mRS scores by 1–2 points manifested improved gait, posture, balance and decreased stiffness, spasms, and startle response; some patients using a wheelchair and those ambulating with devices walked unassisted. In 25% of responders, treatment benefit was sustained for a 40-month median period, but in 29.1%, it declined over a 39-month period; 12.5% exhibited a conditioning effect. Three of 5 patients with cerebellar GAD-SPS variant also improved over time. The 12 patients who did not respond the first 3 months remained unresponsive even if IVIg continued for several months.

Discussion

This is a large study in 36 patients with SPS demonstrating that monthly maintenance IVIg therapy offers long-term benefits in 67% of patients for a median 3.3-year period. Because 29.1% experienced diminishing benefit over time due to disease progression, the study highlights the need for more effective therapies.

From the Department of Neurology (J.Y., M.C.D.), Thomas Jefferson University, Philadelphia, PA; and National and Kapodistrian University of Athens (M.C.D.).

Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

GAD = glutamic acid decarboxylase; **IVIg** = intravenous immunoglobulin; **mRS** = modified Rankin Scale; **SPS** = stiff-person syndrome.

Stiff-person syndrome (SPS) is an autoimmune disorder characterized by simultaneous contraction of agonist and antagonist muscles, resulting in muscle rigidity and stiffness.¹⁻⁵ Diagnostic criteria for SPS include stiffness of the limbs and axial muscles, particularly abdominal and thoracolumbar paraspinals; superimposed painful spasms precipitated by emotional distress or unexpected tactile or auditory stimuli; and high (>1: 10,000 by ELISA) serum antiglutamic acid decarboxylase (GAD)-65 antibody titers in up to 80% of the patients.^{1,4} Detailed follow-up data from 53 sequentially studied patients have shown that without immunotherapy, SPS is a progressive disease leading to cumulative physical disability over time even with the use of antispasmodic medications such as baclofen, diazepam, and gabapentin.⁶

Among the immunotherapeutic agents, high-dose intravenous immunoglobulin (IVIg) is currently the preferred treatment for patients with SPS who do not achieve symptom control with muscle relaxants and benzodiazepines, based on a placebo-controlled randomized trial that had shown that high-dose IVIg significantly improves stiffness, spasms, and gait, over a 3-month study period.⁷ Because SPS is a progressive disease, IVIg is currently used as a chronic monthly treatment, although long-term efficacy data are lacking. As a result, there is significant overuse while a placebo or conditioning effect, common in one-third of patients receiving chronic IVIg therapy, is likely overlooked.^{8,9}

Considering that SPS is a rare disease, it is not practical to perform a prospective long-term controlled study, while giving placebo over long periods may raise clinical ethics issues. Careful data collection in well-characterized patients followed by the same physicians using dependency tests to distinguish true treatment benefit from a conditioning or a placebo effect, as previously witnessed in a controlled study with rituximab,¹⁰ is a realistic option to document long-term efficacy. Apart from 2 small studies with 2–5 patients over short time periods using subcutaneous immunoglobulin,^{11,12} there is only one relatively large size study in 19 patients receiving IVIg¹³ that was based on retrospective data collected using a patient-reported scoring system without performing dependency tests to objectively assess efficacy.

The present study describes long-term data from the largest cohort of patients with SPS treated monthly with IVIg and followed over the last 10 years at a single academic center by the same clinicians with expertise in SPS, including the

performance of 2 controlled trials,^{7,10} adhering to the same clinical criteria. Importantly, this is also the first study evaluating long-term IVIg benefits trying to distinguish treatment response from placebo or conditioning effects by performing IVIg dependency trials.⁸

Methods

All adults over the age of 18 with typical SPS,¹ diagnosed by the same neurologists based on the previously published diagnostic criteria^{1,2,7} and followed in our clinic within the last 10 years (2011–2021) were included in the study analysis. All patients received IVIg as prescribed and monitored by the same lead clinician and/or his trainees.

Data collected included demographic information, anti-GAD Ab status, when symptoms started, duration and doses of treatment with IVIg, patients' subjective treatment response, physician-observed effects of IVIg, frequency of dependency trials (or their equivalent), modified Rankin Scale (mRS) scores, and estimated duration of meaningful benefit from IVIg. Response to IVIg was analyzed using both patients' subjective report of symptom improvement and physician assessments. After initiation of IVIg, patients underwent dependency trials when clinical improvement plateaued to confirm continuing need for therapy. A formal dependency trial was performed in patients receiving IVIg by holding doses, prolonging the frequency of IVIg infusions to more than 4 weeks, or decreasing the monthly IVIg dose to assess for recurrence of symptoms or regression of symptom severity, as previously discussed.⁸ Other equivalents to a formal dependency trial involved missed doses due to insurance issues or the COVID-19 pandemic or observing a wearing-off effect in between IVIg doses. Of importance, the subgroup analysis was precisely performed to distinguish the patients who did not undergo dependency trials from those who did. A modified Rankin Scale score was calculated based on documentation before starting IVIg, after the first few months of full IVIg dose, and at follow up visits while on maintenance therapy to evaluate for functional improvement. A clinically meaningful response to IVIg was defined by a change in the mRS score after IVIg treatment; improvement in physician-assessed stiffness, balance, and gait; or a decline in stiffness, balance, gait, and daily functioning with dependency trials. Duration of meaningful benefit was calculated based on patient and physician assessment of when treatment with IVIg no longer produced clinically meaningful changes.

IVIg dosing was also taken into consideration based on the information available in the records. Every patient was generally treated first with an IVIg dose of 2 g/kg of body weight

Table 1 Characteristics of Patients With SPS Who Responded to Long-term IVIg Maintenance Therapy (IVIg Responders)

ID #	Age/sex	Time from symptom onset to diagnosis (y)	Time from symptom onset to treatment with IVIg (y)	GAD antibody positivity	Type of responder	Dependency trials	Total duration of IVIg (mo)	Estimated duration of clinical benefit (mo)	IVIg benefit
R1	55/F	9	11	GAD Ab (+)	Continued benefit	Wearing-off effect	38	38	Decreased spasms and improved gait
R2	41/F	0	0	GAD Ab (+)	Continued benefit	Wearing-off effect	42	42	Decreased spasms and improved gait (mRS score 4 → 2)
R3	32/F	14	Cannot determine	GAD Ab (+)	Continued benefit	Wearing-off effect	At least 55	At least 55	Decreased spasms
R4	49/F	1	1	GAD Ab (+)	Continued benefit	None, recently started IVIg	13	13	Decreased stiffness and back pain; improved gait (mRS score 3 → 2)
R5	54/F	2	4	GAD Ab (+)	Continued benefit	None	At least 28	At least 28	Improved function and gait (mRS score 4 → 3)
R6	78/F	11	14	GAD Ab (+)	Continued benefit	Wearing-off effect	62	62	Unspecified
R7	47/F	3	3	GAD Ab (+)	Decreasing benefit	Wearing-off effect; decreased frequency	41	19	Improved walking, stiffness, flexibility, facial expression, and dysarthria
R8	59/F	Cannot determine	Cannot determine	GAD Ab (+)	Decreasing benefit	Wearing-off effect	At least 16	Cannot determine	Unspecified
R9	40/F	7	8	GAD Ab (-)	Decreasing benefit	Wearing-off; decreased frequency and dose	22	22	Increased energy; decreased pain and spasms; improved gait
R10	72/F	26	26	GAD Ab (+)	Decreasing benefit	Missed dose due to COVID	63	50	Improved gait and balance; decreased spasms; decreased pain (mRS score 3 → 2)
R11	53/M	1	1	GAD Ab (+)	Decreasing benefit	6-mo gap without insurance	31	31	Improved gait and walking speed and faster speech (mRS score 4 → 3)
R12	57/F	1	1	GAD Ab (+)	Decreasing benefit	Decreased frequency during COVID	121	Cannot determine	Improved pain, stiffness, and gait
R13	59/M	1	2	GAD Ab (+)	Decreasing benefit	Wearing-off effect; dose held	39	39	Improved balance and gait; decreased rotary nystagmus and rigidity
R14	60/F	6	8	GAD Ab (+)	No dependency trial	None	At least 58	Cannot determine	Decreased stiffness and spasms
R15	73 (now deceased)/F	4	0	GAD Ab (+)	No dependency trial	None	143	Cannot determine	Unspecified
R16	56/F	2	4	GAD Ab (+)	No dependency trial	None	90	Cannot determine	Improved gait; decreased stiffness and spasms (mRS score 4 → 2)
R17	51/F	7	8	GAD Ab (+)	No dependency trial	None	At least 23	Cannot determine	Improved gait, decreased stiffness


Continued

Table 1 Characteristics of Patients With SPS Who Responded to Long-term IVIg Maintenance Therapy (IVIg Responders) (*continued*)

ID #	Age/sex	Time from symptom onset to diagnosis (y)	Time from symptom onset to treatment with IVIg (y)	GAD antibody positivity	Type of responder	Dependency trials	Total duration of IVIg (mo)	Estimated duration of clinical benefit (mo)	IVIg benefit
R18	57/F	0	0	GAD Ab (+)	No dependency trial	None	13	Cannot determine	Decreased stiffness
R19	74/F	1	1	GAD Ab (+)	Conditioning effect	Dose held; dose decreased	58	54	Improved gait and mobility; decreased stiffness and pain (mRS score 4 → 3)
R20	60/M	Cannot determine	Cannot determine	GAD Ab (+)	Conditioning effect	Doses held for 6 mo after PE; dose held; wearing-off effect	23	20	Decreased spasms and stiffness; decreased startle response
R21	62/F	Cannot determine	Cannot determine	GAD Ab (+)	Conditioning effect	Wearing-off effect; decreased frequency due to insurance; decreased dose	216	205	Improved mobility; decreased spasms and stiffness
R22	72/F	3	3	GAD Ab (+)	Discontinued prematurely	N/A	48	N/A	Improved gait; decreased spasms and stiffness
R23	68/F	5	8	GAD Ab (-)	Decreasing benefit over time; discontinued prematurely	Wearing-off effect; dose held	12	N/A	Improved balance, walking speed, and posture; decreased startle response and spasms
R24	61/F	0	1	GAD Ab (+)	Discontinued prematurely	Dose held	11	N/A	Improved gait; decreased stiffness (mRS score 4 → 3)

Abbreviations: IVIg = intravenous immunoglobulin; mRS= modified Rankin Scale; N/A = not applicable; SPS = stiff-person syndrome.

Figure 1 Median Duration and Range of IVIg Treatment in 36 Patients With Stiff-Person Syndrome Categorized as IVIg Responders or Nonresponders



IVIg responders were subcategorized based on their response to long-term treatment—continued benefit over time, decreasing benefit over time, demonstration of a conditioning effect, not assessed with a dependency trial, or unable to assess due to premature discontinuation of therapy.

for at least 3 months, as in our original IVIg trial.⁷ The subsequent maintenance IVIg doses either remained the same (2 g/kg per month) throughout the follow-up period or varied from 1 to 2 g/kg every 3–6 weeks based on the results of dependency tests, as per standard IVIg maintenance protocol for all neurologic disorders.⁸

Data Availability

Data not provided in the article due to space limitations may be shared (anonymized) at the request of any qualified investigator for purposes of replicating the results.

Standard Protocol Approvals, Registrations, and Patient Consents

Chart review and data analysis were approved by the IRB of the Jefferson Office of Human Research (MCD: principal investigator). Patient consent was not required for this retrospective chart review.

Results

Demographics

The study included 36 patients, 29 women and 7 men, of median age 58 years (range 32–81 years). Time from symptom onset to SPS diagnosis ranged from 0 years (diagnosed the same year as symptom onset) to 26 years, with a median of 3.5 years. Time from symptom onset to treatment with IVIg ranged from 0 years (treated the same year as symptom onset) to 26 years with a median of 4 years. Thirty-two of the 36 patients were positive for GAD-65 antibodies with high titers, as previously specified^{1,4,14-16}; 4 patients were diagnosed with seronegative SPS based on all the other required criteria and exclusions^{4,5} (Table 1, eTable 1, links.lww.com/NXI/A732). Five GAD-positive patients also had cerebellar involvement, as part of GAD-SPS spectrum disorder.^{4,5,17}

Overall Clinical Changes and Benefits From IVIg


Of the 36 patients, 24 (67%) had a clinically significant response to treatment with IVIg, similar to what was noted in our original short-term (3-month) controlled study,⁷ with benefit extended up to a median period of 40 months (Figure 1). Of the 4 patients with seronegative SPS, 2 improved with IVIg; 1 had complications and discontinued treatment after a single dose, and the fourth did not respond to IVIg. Subjectively, the responders reported the following overall long-term experience with IVIg: improved gait, improved daily functioning, improved balance, decreased dysarthria and faster speech, decreased stiffness, decreased painful spasms, improved energy, decreased startle response, improved posture, and improved facial expression (Table 1). Based on objective neurologic examinations, responders were noted to have decreased rigidity, improved gait, improved facial expression, decreased nystagmus, and decreased dysarthria (in the patients with SPS and cerebellar findings).

Among the 36 patients who received IVIg, 12 patients did not exhibit any benefit (as defined above), at any time during a median of 3 months (range 1–24 months) of IVIg treatment (Figure 1; eTable 1, links.lww.com/NXI/A732). No differences in the clinical phenotype, GAD Ab status, or symptomatology characteristics were noted between the responders and nonresponders.

Response Assessed by the Modified Rankin Scale Score

Of the 24 IVIg responders, 8 patients (33%) responded to the extent that their modified Rankin Scale score improved by 1 point (in 6 patients) or by 2 points (in 2 patients), most dramatically illustrated by the ability to walk without an assistive device after treatment. Specifically, 6 of these patients were using a wheelchair before starting IVIg but became able to walk independently (R2 and R16; Table 1) or with a cane

Figure 2 Relative Proportion of Patients With Stiff-Person Syndrome Who Responded to IVIg Therapy in Each Subcategory of Responders With the Median Duration and Range of Treatment for Each Category



or walker (R5, R11, R19, and R24; Table 1) several months after IVIg; 2 others who required a cane or a walker to walk pre-IVIg became able to walk without assistance after several IVIg courses (R4, R10; Table 1). The other 16 responders maintained the same mRS score after long-term IVIg treatments, demonstrating a stabilizing effect.

Duration of Long-term Benefit of IVIg and Dependency Tests

For the 24 IVIg responders, the duration of treatment ranged from 11 to 216 months, with a median of 40 months (Figure 1). Sixteen of the 24 responders underwent formal dependency trials or an equivalent. After holding their IVIg infusions, reducing the monthly IVIg dose from 2 g/kg to 1 g/kg or prolonging the frequency of the infusions, there was a clear symptom recurrence indicating that maintenance therapy was beneficial and still needed. One patient (R1; Table 1) who declined further when IVIg was held due to poor venous access exhibited a satisfactory clinical response with less side effects when switched to SCIg; in this patient, SCIg continues to ensure improvement and stability for the last 2 years. Eight of the 24 responders continued receiving treatment without undergoing a formal dependency test (Figure 2); 2 of these patients continued to experience clear benefit and were categorized in Table 1 in the responders with continued benefit subgroup; another prematurely discontinued therapy because of medical comorbidities and was categorized in Table 1 in the discontinued prematurely subgroup; the remaining 5 continued on IVIg for a median of 58 months (range 13–143 months) because it was felt to be beneficial and were categorized in Table 1 in the responders with no dependency trial subgroup.

Subgroup Analysis of Long-term Responders Based on Continuing Stability, Declined Benefit, Conditioning Effect, or Safety Issues

Of the 24 patients who benefited from IVIg with a high maintenance dose of 2 g/kg per month, 6 patients (25%) with active disease continued to experience and exhibit clinically

meaningful benefit for a median duration of 40 months (range 13–62 months) (Figure 1). Seven other patients (29.1%) also exhibited clinically meaningful improvement based on dependency trials for a median of 39 months (range 16–121 months), but started to notice a decreasing relative treatment benefit after an estimated median of 31 months (range 19–50 months), despite receiving high-dose IVIg treatments (Figure 2 and Table 1).

Three of the 24 responders (12.5%) (Figure 2) who initially demonstrated clear benefit experienced decreasing benefit over time but were continued on maintenance therapy despite a lack of objective decline with dependency tests. These patients requested continuation of IVIg therapy, citing increased fatigue and pain without treatment and expressing fear that their functional status would decline if not continued on maintenance therapy, exhibiting a form of conditioning effect.^{8,9} This patient subgroup remained on maintenance therapy for a median duration of 58 months (range 23–216 months) (Figure 2).

Of the 24 patients who benefited from IVIg, 3 patients (12.5%) prematurely discontinued treatment after a median period of 12 months (range 11–48 months) due to other medical comorbidities (Figures 1 and 2). One patient discontinued IVIg due to cardiac risk factors, another due to starting other immunotherapies for rheumatologic conditions, and the third as advised due to a prior intracerebral hemorrhage considered unrelated to IVIg. Overall, other than the common and mild infusion-related reactions,⁸ no major adverse events were observed with the chronic IVIg treatments.

GAD-Positive Patients With SPS With Cerebellar Involvement (GAD-SPS Spectrum)

Five GAD-positive patients with SPS also had cerebellar findings with ataxia and dysarthria, consistent with GAD-SD.^{4,5,10} Three of these patients (R7, R11, and R13; Table 1) exhibited a beneficial response to IVIg with objective improvement in speech, balance, and nystagmus but with

decreasing benefit over time. One patient (R11, Table 1) had a substantial response with improvement in the mRS score, going from being a wheelchair user before IVIg to being able to walk with a walker after IVIg; he gradually exhibited, however, decreasing benefit and switched to rituximab. Two other patients (NR3 and NR8; eTable 1, [links.lww.com/NXI/A732](https://www.lww.com/NXI/A732)) did not show convincing signs of improvement and were categorized as nonresponders, although 1 patient noted a mild but transient improvement in gait.

Discussion

The study demonstrates that maintenance therapy with IVIg continues to be effective over a median of 3.3 years in 67% of patients with typical SPS, improving daily functioning, gait, balance, painful spasms, posture, and facial expression with a demonstrable effect in decreasing stiffness, spasms and startle response. Although uncontrolled due to disease rarity and clinical ethics to give placebo over 2–3 years, this is a long-term study in a large group of patients with SPS seen over time by the same experienced clinicians that documents continued IVIg efficacy based on a combination of mRS scores, dependency tests, and objective clinical observations. The results complement the conclusions from the original short-term 3-month controlled study that the same investigators conducted 20 years ago with a much smaller number of enrolled patients.⁷ The present analysis, however, highlights several additional observations of increased clinical and practical importance.

First, 33% of responders experienced improvement in their main disabling symptoms over time substantial enough to improve their mRS score by 1 or 2 points; patients who were using a wheelchair or unable to ambulate independently before receiving IVIg became able to walk with an assistive device or independently with maintenance therapy. This demonstrates that a subset of patients can achieve and maintain major functional improvement with monthly IVIg. Given that in a longitudinal study patients with SPS manifested disabling progression over a 2–4-year observational period,⁶ the present data show that maintenance IVIg therapy provides a stabilizing effect and may delay disease progression.

Second, among all IVIg responders, 25% continued to experience persistent benefit for a median period of 40 months (range 13–62 months); 29.1% of them, however, started to experience diminishing relative benefit after an estimated median period of 31 months. Such a declining efficacy was not related to prolonged infusion frequency or reduced IVIg dosing, given that patients continued on a high dose of 2 g/kg per month as determined by the dependency tests, but it rather represents reduced effect most likely due to disease progression. As stated earlier, the longitudinal study with 57 GAD-positive patients with SPS examined and followed at the NIH every 6 months for a 2-year period by the same clinicians as in this study had shown that SPS is a progressive disease; 80% lost the ability to walk independently after a 2-year follow-up period without immunotherapy, exhibiting increased stiffness and heightened sensitivity scores, worsening functional

status, higher frequency of falls, and impaired ability to walk independently or perform work duties.⁶ Importantly, after the first two-year follow up period, 5 patients could no longer function with only antispasmodic therapy and required intermittent IVIg infusions with considerable benefit.⁶ On this basis, the present study suggests that IVIg may inhibit disability progression for a period of time in a considerable subset of patients with SPS, but the observation that 33% of patients did not respond and that 29.1% exhibited decreasing benefit over time highlights the need for more effective maintenance therapies, especially at the time when the benefit of IVIg starts to decline.

Third, a small (12.5%) patient subset with demonstrable initial improvement felt the need to continue on maintenance IVIg for a median of 58-month observational period, despite acknowledging no significant objective difference with dependency tests. These patients asserted that IVIg was helpful in reducing fatigue and pain, while expressing fear that they would decline if not continued on maintenance therapy. Such a conditioning effect, initially observed in patients with CIDP receiving maintenance IVIg therapy,⁹ has now been observed in patients with other autoimmune neurologic conditions on chronic IVIg therapy.⁸ In the 2 large controlled CIDP trials, ICE and PATH, 37% of patients randomized to placebo remained stable for a 24-week study period, even if they were previously observed to be IVIg-dependent.^{8,9} Because a placebo effect has been also noted in our randomized trial on patients with SPS receiving rituximab,¹⁰ a placebo component cannot be excluded among the small number of those patients in the present study who exhibited benefit but did not undergo dependency trials. Carefully performing periodic dependency trials in patients with SPS receiving chronic IVIg therapy remains fundamental to avoid overuse; furthermore, educating patients from the outset of potential risks is essential, especially in poorly mobilized patients with SPS with other comorbidities, such as insulin-dependent diabetes who are at risk for thrombosis and other adverse effects.⁸ The observation that 33% of patients who did not respond to IVIg during the first 3 months did not also respond even when therapy continued for up to 20 months underscores the need for prudent use of IVIg in clinical practice to avoid overuse.

Fourth, long-term high-dose IVIg tolerance was very good with only 3 of the 24 responders discontinuing therapy prematurely due to IVIg-related side effects or other medical comorbidities. Two of the nonresponders also had IVIg-related side effects or medical comorbidities preventing continued use.

Despite some study limitations, mainly the lack of a control group due to obvious difficulties in giving placebo for long periods in a rare disease and the constraints of a retrospective chart review, this study has conclusively demonstrated the effectiveness of IVIg as chronic maintenance therapy while highlighting the need for new or novel therapies for the chronic management of SPS. Promising immunotherapies should be, however, tested in a randomized controlled design, as done with the rituximab trial,¹⁰ but in a larger number of patients involving many centers, or as concluded from the results of the large but uncontrolled hematopoietic stem cell transplantation

study that led to early termination.^{18,19} Although both of these studies failed to show efficacy, rituximab and autologous hematopoietic stem cell transplantation can still provide benefit in some patients with SPS over a long time period.^{10,20,21}

Acknowledgment

The authors express their deep appreciation to Dr. Goran Rakocevic who had also seen many of the reviewed patients and has participated with Dr. Dalakas in several studies on stiff-person syndrome, both at the NIH and while at Thomas Jefferson University over many years.

Study Funding

The authors report no targeted funding.

Disclosure

None to report. Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures.

Publication History

Received by *Neurology: Neuroimmunology & Neuroinflammation* March 26, 2022. Accepted in final form May 10, 2022. Submitted and externally peer reviewed. The handling editor was Josep Dalmau, MD, FAAN.

Appendix Authors

Name	Location	Contribution
Jessica Yi, MD	Department of Neurology, Thomas Jefferson University, Philadelphia, PA	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data
Marinos C. Dalakas, MD, FAAN	Department of Neurology, Thomas Jefferson University, Philadelphia, PA; National and Kapodistrian University of Athens	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data

References

- Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. *Neurology*. 2000;55(10):1531-1535.
- Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. *Ann Intern Med*. 1999;131(7):522-530.
- McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. *Arch Neurol*. 2012;69(2):230-238.
- Dalakas MC. Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. *Neurotherapeutics*. 2022. doi: 10.1007/s13311-022-01188-w.
- Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders - insights and challenges. *Nat Rev Neurol*. 2020;16(7):353-365.
- Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. *BMC Neurol*. 2019;19(1):1.
- Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. *N Engl J Med*. 2001;345(26):1870-1876.
- Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. *Neurotherapeutics*. 2021;11:1-22.
- Lewis RA, Cornblath DR, Hartung HP, et al. PATH study group. Placebo effect in chronic inflammatory demyelinating polyneuropathy: the PATH study and a systematic review. *J Peripher Nerv Syst*. 2020;25(3):230-237.
- Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. *Ann Neurol*. 2017;82(2):271-277.
- Aljarallah S, Newsome SD. Use of subcutaneous immunoglobulin in stiff person syndrome: case series. *Medicine (Baltimore)*. 2021;100(12):e25260.
- Fileccia E, Rinaldi R, Minicuci GM, et al. Subcutaneous immunoglobulin for maintenance therapy in stiff-person syndrome: one-year follow-up in two patients. *Neuromuscul Disord*. 2020;30(11):921-924.
- Bose S, Thompson JP, Sadalage G, Karim A, Jacob S. Quantitative assessment of response to long-term treatment with intravenous immunoglobulin in patients with stiff person syndrome. *Mov Disord Clin Pract*. 2021;8(6):868-874.
- Munoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment. *Neurol Neuroimmunol Neuroinflamm*. 2020;7:e696.
- Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. *Neurology*. 2001;57(5):780-784.
- McKeon A, Tracy JA. GAD65 neurological autoimmunity. *Muscle Nerve*. 2017;56(1):15-27.
- Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. *Neurology*. 2006;67(6):1068-1070.
- Burt RK, Balabanov R, Han X, et al. Autologous hematopoietic stem cell transplantation for Stiff Person Spectrum Disorder: a clinical trial. *Neurology*. 2021;96(6):e817-e830.
- Dalakas MC. A HSCT trial in stiff person syndrome: limited benefits halt enrollment but should be more to come? *Neurology*. 2021;96(6):239-240.
- Kass-Iliyya L, Snowden JA, Thorpe A, et al. Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. *J Neurol*. 2021;268(1):265-275.
- Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff person syndrome with rituximab. *J Neurol Neurosurg Psychiatry*. 2005;76(7):999-1001.

Neurology[®] Neuroimmunology & Neuroinflammation

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome

Jessica Yi and Marinos C. Dalakas
Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000200011

This information is current as of July 7, 2022

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/9/5/e200011.full.html
References	This article cites 21 articles, 2 of which you can access for free at: http://nn.neurology.org/content/9/5/e200011.full.html##ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.

